MESO
Mesoblast Ltd
NASDAQ: MESO · HEALTHCARE · BIOTECHNOLOGY
$15.55
+2.17% today
Updated 2026-04-29
Market cap
$2.01B
P/E ratio
—
P/S ratio
30.75x
EPS (TTM)
$-0.74
Dividend yield
—
52W range
$10 – $22
Volume
0.3M
Mesoblast Ltd (MESO) Financial statements
SEC filings — annual and quarterly data.
Profit margin
-144.30%
Operating margin
-55.20%
ROE
-18.20%
ROA
-6.16%
Debt/equity
—
Margin trends — annual
Gross margin Operating margin Profit margin
| Year | Revenue | Net income | Gross margin | Op. margin | Profit margin |
|---|---|---|---|---|---|
| 2006 | $2.82M | $-8.30M | 100.00% | -222.70% | -294.09% |
| 2007 | $1.68M | $-8.73M | 100.00% | -417.64% | -519.74% |
| 2008 | $909807.00 | $-10.06M | 100.00% | -872.67% | -1,105.99% |
| 2009 | $890708.00 | $-12.29M | 100.00% | -1,058.60% | -1,379.29% |
| 2010 | $5500.00 | $-14.78M | 100.00% | -188,851.78% | -268,743.55% |
| 2011 | $120.92M | $90.61M | 100.00% | 77.54% | 74.93% |
| 2012 | $38.28M | $-71.15M | 100.00% | -127.28% | -185.86% |
| 2013 | $28.79M | $-61.66M | 26.12% | -208.71% | -214.21% |
| 2014 | $25.98M | $-80.96M | 2.10% | -278.58% | -311.62% |
| 2015 | $23.75M | $-119.37M | -0.15% | -477.48% | -502.64% |
| 2016 | $42.55M | $-4.13M | 30.05% | -131.35% | -9.70% |
| 2017 | $2.41M | $-76.81M | -400.21% | -3,733.08% | -3,184.70% |
| 2018 | $17.34M | $-35.29M | 68.24% | -445.99% | -203.51% |
| 2019 | $16.72M | $-89.80M | -349.55% | -479.62% | -537.01% |
| 2020 | $32.16M | $-77.94M | -153.44% | -232.84% | -242.38% |
| 2021 | $7.46M | $-98.81M | -1,049.83% | -1,463.20% | -1,325.25% |
| 2022 | $10.21M | $-91.35M | -522.58% | -789.09% | -894.59% |
| 2023 | $7.50M | $-81.89M | -632.20% | -923.73% | -1,091.71% |
| 2024 | $5.90M | $-87.96M | -595.87% | -1,425.74% | -1,490.27% |
| 2025 | $17.20M | $-102.14M | 70.17% | -363.08% | -593.92% |